Cargando…
SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187842/ https://www.ncbi.nlm.nih.gov/pubmed/32360437 http://dx.doi.org/10.1016/j.bbi.2020.04.079 |
| _version_ | 1783527235018293248 |
|---|---|
| author | Byrareddy, Siddappa N. Mohan, Mahesh |
| author_facet | Byrareddy, Siddappa N. Mohan, Mahesh |
| author_sort | Byrareddy, Siddappa N. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7187842 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71878422020-04-28 SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? Byrareddy, Siddappa N. Mohan, Mahesh Brain Behav Immun Article Elsevier Inc. 2020-07 2020-04-28 /pmc/articles/PMC7187842/ /pubmed/32360437 http://dx.doi.org/10.1016/j.bbi.2020.04.079 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Byrareddy, Siddappa N. Mohan, Mahesh SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title | SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title_full | SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title_fullStr | SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title_full_unstemmed | SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title_short | SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| title_sort | sars-cov2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation? |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187842/ https://www.ncbi.nlm.nih.gov/pubmed/32360437 http://dx.doi.org/10.1016/j.bbi.2020.04.079 |
| work_keys_str_mv | AT byrareddysiddappan sarscov2inducedrespiratorydistresscancannabinoidsbeaddedtoantiviraltherapiestoreducelunginflammation AT mohanmahesh sarscov2inducedrespiratorydistresscancannabinoidsbeaddedtoantiviraltherapiestoreducelunginflammation |